Vancouver, BC, CANADA (August 26, 2002) Transfusion experts gathered from around the world in Vancouver for the 27th Congress of the International Society of Blood Transfusion (ISBT) Meeting will hear Vitex present further efficacy and safety data on its INACTINETM red blood cell technology. V.I. Technologies, Inc. (Vitex) (Nasdaq: VITX), a biotechnology company dedicated to developing products that improve the safety and availability of the transfusion blood supply by pathogen reduction or removal, reported today that its INACTINETM technology was successful in eradicating the parasites that cause Chagas' Disease, malaria and babesiosis in red blood cells. The company also presented its overall clinical development program for INACTINETM red blood cells including results of completed clinical trials. Additional study data on the chemistry and safety profile for the INACTINETM pathogen reduction system will be presented in three scientific posters on Tuesday, August 27, the company announced.

"These studies validate the unmatched capabilities of the INACTINETM pathogen reduction system for red cells in reducing infectious disease risks of blood transfusions, as well as building upon the product's safety profile," said John R. Barr, CEO of Vitex. "Ongoing research and development of the INACTINETM pathogen reduction system demonstrates Vitex's commitment to enhancing the safety and availability of the world's blood supply."

In the first study, titled "The INACTINETM PEN110 Chemistry Eradicates the Parasites that Cause Chagas' Disease, Malaria, and Babesiosis," the causative parasites Trypanasoma cruzi, Plasmodium falciparum, and Babesia microti, respectively, were evaluated for inactivation using standard INACTINETM PEN110 red blood cell process conditions. The results showed that the INACTINETM PEN110 treatment
'"/>

Contact: Matthew Scampoli
m.scampoli@nrp-euro.com
212-845-4256
Noonan/Russo Communications
26-Aug-2002

Page: 1 2
Related biology news :

1. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
2. Scientists question reports of massive ant supercolonies in California and Europe
3. Survey reports fall in stem cell transplants for breast cancer
4. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
5. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine
6. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
7. Measles on the rise as vaccinations fall in the UK, Science study reports
8. WCS biologist George Schaller reports surprising increase in Tibets wildlife
9. Clinical study reports findings of combination therapy with DOXIL
10. Europes population has developed new tendency to shrink, Science study reports
11. U of A scientist finds Atlantic salmon escapes higher than government reports